Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, ten have given a buy recommendation and four have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $67.67.

Several research analysts recently commented on SRRK shares. Wedbush reiterated an “outperform” rating and issued a $64.00 target price on shares of Scholar Rock in a report on Tuesday, September 15th. JPMorgan Chase & Co. lifted their price target on shares of Scholar Rock from $63.00 to $70.00 and gave the stock an “overweight” rating in a research note on Monday, September 21st. Citigroup upped their target price on shares of Scholar Rock from $60.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, September 14th. Jefferies Financial Group upped their price objective on Scholar Rock from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, September 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, October 15th.

Check Out Our Latest Stock Report on Scholar Rock

Insiders Place Their Bets

In other news, Director Srinivas Akkaraju acquired 146,970 shares of the company’s stock in a transaction on Monday, October 26th. The stock was purchased at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the acquisition, the director owned 6,380,517 shares of the company’s stock, valued at $265,365,702.03. This trade represents a 2.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently made changes to their positions in SRRK. BlackRock Inc. acquired a new stake in Scholar Rock during the 2nd quarter valued at $522,175,000. Redmile Group LLC raised its position in shares of Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock valued at $445,715,000 after purchasing an additional 3,845,775 shares during the period. Jupiter Topco LLC acquired a new stake in shares of Scholar Rock during the 2nd quarter worth about $123,279,000. Bank of America Corp DE acquired a new stake in shares of Scholar Rock during the 2nd quarter worth about $53,474,000. Finally, Eagle Health Investments LP bought a new stake in shares of Scholar Rock during the 2nd quarter worth about $30,540,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Down 2.3%

Shares of Scholar Rock stock opened at $42.91 on Tuesday. The stock has a 50-day simple moving average of $48.20 and a 200-day simple moving average of $48.18. Scholar Rock has a 52-week low of $27.07 and a 52-week high of $61.76. The firm has a market cap of $5.23 billion, a price-to-earnings ratio of -12.44 and a beta of 0.61. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.84). During the same quarter last year, the business posted ($0.98) earnings per share. On average, equities research analysts expect that Scholar Rock will post -3.29 earnings per share for the current fiscal year.

About Scholar Rock

(Get Free Report)

Scholar Rock, Inc is a biotechnology company focused on developing medicines that selectively target growth factors in the transforming growth factor beta (TGF-β) superfamily. The company’s research is intended to address serious diseases in which these signaling pathways play an important role, including neuromuscular and metabolic conditions.

Scholar Rock’s lead investigational product is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that limits muscle growth.

See Also

Analyst Recommendations for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.